CRISPR-Cas Clinical Trial Update
Nov. 17, 2020
Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.
Always stay updated with the free CMN Newsletter.
Shanghai BDgene Technology
Main focus: mRNA-mediated delivery of gene-editing systems
Company stage: Clinical
Diseases: wet age-related macular degeneration (wAMD), glucoma, multiple other undisclosed diseases
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Shanghai, China
Website: https://bdgenetherapeutics.com/
Shanghai BDgene Technology uses it proprietary technology, BDmRNA, to deliver gene-editing systems for the treatment of genetic diseases. The technology is thought to reduce the probability of off-target gene editing, and improve the safety of gene-editing medicines. Currently, the company is developing multiple pre-clinical programmes.
